Albert Pujols is in a 5-for-50 slump

15 Comments

Not only hasn’t Albert Pujols started producing like his usual self following a rough start to the season, he’s actually getting worse.

Pujols went 3-for-5 with three doubles on April 19, which was his first game with multiple extra-base hits and seemingly signaled that he was starting to come around. Instead he’s gone 5-for-50 (.100) since then, lowering his batting average from .296 to .202 and lowering his OPS from .759 to .524.

Within the 5-for-50 slump Pujols has drawn just two non-intentional walks while striking out eight times, which is very uncharacteristic for someone with significantly more walks (981) than strikeouts (718) for his entire career.

And of course he’s yet to homer for the Angels in 110 plate appearances.

There are 190 hitters with enough plate appearances to qualify for the batting title and 180 of them have a higher OPS than Pujols, including Chone Figgins, Clint Barmes, Jamey Carroll, Cliff Pennington, Scott Rolen, Dee Gordon, Alfonso Soriano, Ike Davis, Brandon Crawford, Drew Stubbs, Miguel Olivo, and Ian Stewart.

Oh, and the guy who replaced him in St. Louis too.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.